Arginine modified chitosan/polyvinyl alcohol hydrogel microneedle transdermal delivery patches for wound healing

2:

• The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the arginine-modified chitosan is prepared by modifying 5 mL of a 0.3% (w/v) chitosan solution at pH 5.5 with 3 mL of a 0.04 mM arginine solution, preactivated with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.

3:

• The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the concentration of PVA ranges from 10% to 12% (w/v).

4:

• The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the arginine-modified chitosan and PVA solutions are mixed in a 1:2 ratio by volume.

5:

• The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the concentration of the crosslinker, trimethyl orthoformate (TMOF), is 4% (v/v) relative to the total volume of the polymeric mixture.

6:

• The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the patch comprises a 15×15 array of pyramidal microneedles, with each microneedle having an average height of 340±5 μm and an average base length of 244±3 μm.

7:

• The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the patch is designed for the transdermal delivery of curcumin as a therapeutic agent, and further incorporates 1 mL of 2 mg/mL methanolic curcumin.

8:

• The hydrogel microneedle-based transdermal delivery patch of claim 7, wherein the curcumin amount is 120 μg per patch.

9:

• The hydrogel microneedle-based transdermal delivery patch of claim 7, wherein the patch demonstrates a 70% release of the loaded curcumin over a 48-hour period in a controlled-release manner.

10:

• The hydrogel microneedle-based transdermal delivery patch of claim 7, wherein the patch demonstrates healing of animal wounds.